Coherus Oncology (CHRS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of$0.32. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.13$0.31 per share when it actually produced a loss of $0.34, delivering a surprise of -9.68%.Over the last four quarters, the company ha ...